Tumor News and Research

RSS

New mechanism of drug release using 3D superhydrophobic materials

According to a recent study, there is a new mechanism of drug release using 3D superhydrophobic materials that utilizes air as a removable barrier to control the rate at which drug is released.

30 Jan 2012

Researchers develop new MRS technique to diagnose brain tumors

Researchers at UT Southwestern Medical Center have developed what they believe to be the first clinical application of a new imaging technique to diagnose brain tumors.

30 Jan 2012

Researchers identify possible cause for loss of tumor suppressor genes

Researchers at Queen's University in Kingston, Canada have identified a possible cause for the loss of a tumour suppressor gene (known as PTEN) that can lead to the development of more aggressive forms of prostate cancer.

27 Jan 2012

GenPath, BioReference Labs to introduce OnkoMatch solid tumor genotype test

BioReference Laboratories, Inc. and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts General Hospital (MGH) is introducing its groundbreaking solid tumor genotype test.

27 Jan 2012

Scientists connect two signature characteristics of pancreatic cancer

Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.

27 Jan 2012

UCSF team develops methods that may help predict brain tumor recurrence

After people with low-grade glioma, a type of brain cancer, undergo neurosurgery to remove the tumors, they face variable odds of survival - depending largely on how rapidly the cancer recurs. Even though their doctors monitor the tumor closely with sophisticated imaging, it is difficult to determine with certainty whether cancer has returned in a more malignant state that requires aggressive treatment.

25 Jan 2012

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.

25 Jan 2012

Novel detection of ovarian cancer in early stages

Ovarian cancer is often detected at a late stage and it is the leading cause of death due to gynecological cancers, and the sixth leading cause of cancer death in women. According to latest discovery by researchers at Sydney’s Garvan Institute there may be a way this killer cancer is detected earlier.

24 Jan 2012

Five scientists named recipients of Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2012 recipients of the Damon Runyon-Rachleff Innovation Award.

24 Jan 2012

miR-375 can predict life threatening head and neck cancers

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

Haymarket Media launches ChemotherapyAdvisor.com

Haymarket Media Inc., publisher of Monthly Prescribing Reference (MPR), MPR Hematology/Oncology Edition, and Oncology Nurse Advisor (ONA), is pleased to announce the launch of ChemotherapyAdvisor.com, offering oncologists and their support teams a unique clinical decision support tool.

23 Jan 2012

Duke team creates vaccine adjuvant of nanoparticles that target lymph nodes

Researchers at Duke University Medical Center have created synthetic nanoparticles that target lymph nodes and greatly boost vaccine responses, said lead author Ashley St. John, Ph.D., a researcher at Duke-NUS Graduate Medical School.

23 Jan 2012

Study describes new pharmacological resistance to colon cancer

Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer. This new mechanism is a mutation in an oncogene called EGFR (epidermal growth factor receptor) causing resistance to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the EGFR.

23 Jan 2012

Chronic inflammation combines with DNA methylation to promote development of colorectal cancer

Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine.

23 Jan 2012

Doctors can use tactile imaging sensor for early detection of cancerous tumors

A key part of a medical patient's physical examination is performed through touch, but the doctor can only glean so much information from what he feels. That's why Temple University researchers have created a prototype device that will not only emulate human tactile sensation, but quantify it as well.

21 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

RBC storage duration not associated with transfusion-related pulmonary complications

There is no difference in early measures of pulmonary function, immunologic status or coagulation status after fresh versus standard issue single-unit red blood cell (RBC) transfusion, according to a new study from the Mayo Clinic.

21 Jan 2012

New data from Infinity saridegib and gemcitabine Phase 1b/2 combination trial on pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.

20 Jan 2012

Positive preliminary data from Exelixis' cabozantinib phase 2 trial on HCC

Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma (HCC) patients participating in the ongoing phase 2 randomized discontinuation trial (RDT) of cabozantinib.

20 Jan 2012